Mun Hyuk Seong,1 Ho Kil,1 Young Seok Kim,2 Si Hyun Bae,3 Youn Jae Lee,4 Han Chu Lee,5 Byung Hak Kang,6 and Sook-Hyang Jeong1* Clinical and Epidemiological.

Slides:



Advertisements
Similar presentations
Hcv infection and management in advanced liver disease
Advertisements

The effect of improved HCV diagnosis and treatment on public health The effect of improved HCV diagnosis and treatment on public health P Mathurin Hôpital.
Liver Disease and Thalassaemia George Constantinou.
Screening for Hepatitis C Virus Infection Prepared for: Agency for Healthcare Research and Quality (AHRQ)
The changing pattern of viral hepatitis in Saudi Arabia Yousef Qari, MD, FRCP(C), ABIM Gastoenterologist King Abdulaziz University Hospital.
Epidemiology and Control Programs for HBV Infection. Yousef Qari, MD, FRCP(C), ABIM Gastoenterologist King Abdulaziz University Hospital.
Iva Pitner Mentor: A. Žmegač Horvat
National Hepatitis C Database Dr Lelia Thornton Health Protection Surveillance Centre December 2012.
Epidemiology of chronic liver disease in Sudanese children
HIV and Hepatitis C Co-infection Amy Kindrick, M.D., M.P.H. San Francisco AIDS ETC National HIV/AIDS Clinical Consultation Center February 12, 2002.
Module 3: HCV prevalence and course of HCV infection.
Impact of weight management in chronic HCV Egyptian patients on liver fibrosis. By: Dr. Osama A. Fekry Lecturer of CN at the AUC Head of clinical Nutrition.
Epidemiology and Prevention of Viral Hepatitis A to E: Hepatitis D (Delta) Virus Division of Viral Hepatitis.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
World Hepatitis Day 2013, 29 th July Establishing a framework for better data collection and surveillance of Hepatitis in South Africa N. Prabdial-Sing.
A Cluster of Hepatitis C among Rural, Young Adults – Illinois, 2012 Julia Howland, MPH CPH CDC/CSTE Applied Epidemiology Fellow Illinois Department of.
HBV genotyping 12/21/07 Carrie Marshall. Received a send-out request for HBV genotyping on a 52y man.
EPIDEMIOLOGICAL AND CLINICAL FEATURES OF LIVER CIRRHOSIS
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2012.
The Swiss Population In 2001 Resident population: 7,258,500 Population density: 176 per Km 2 Foreign nationals: 20.1% (~1,460,000) Excess of births over.
CLINICAL AND EPIDEMIOLOGICAL ASPECTS OF LIVER CIRRHOSIS AMONG THE YOUNG AND MIDDLE-AGED PATIENTS FIRST AUTHOR: DOLGHII XENIA COAUTHOR(S) : BORDIANU ALEXANDRA,
Hepatitis C in the Elderly Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL MAY 15,
Incidence Hepatocellular Carcinoma is one of the most common malignancies worldwide More common in Asia and Africa than in the United States. The highest.
Sources of Hepatitis C Infection (U.S.) Previously Acquired (
MODEL OF INFECTIOUS DISEASES AND OUTBREAKS IN VIETNAM MILITARY ( ) Sr.Col. Le Ngoc Anh, MD. PhD. Vietnam Military Medical Department.
Sunil Kumar, B.K.Kapoor, Urvinderpal Singh, Vidhu Mittal Department of Pulmonary Medicine, GMC,Patiala PRESENTATION OF PULMONARY TUBERCULOSIS IN ELDERLY.
"Epidemiological Features of Rotavirus Infection among children below 5 years old in Jordan, Rationale for Vaccine Introduction,2015" Kareman Juma`ah Al-Zain.
Seroprevalance of Hepatitis C in Turkey (%) (Anti-HCV positivity in donors) Adana (n:8310) Antalya (n:16.410) Bursa (n:16.512) Erzurum (n:24.870) İstanbul.
Parallel and Overlapping Prevalence of Hepatitis B and C Viruses in Apparently Healthy Individuals in a Northern Nigerian Population Pennap, GRI and Chuga,
Clinical Features and Outcome of Primary Amyloidosis in Korea Kihyun Kim, Seok Jin Kim, Hyun Jung Jun,Yeung-Chul Mun, Chul Soo Kim, Jong-Ho Won, Soo-Mee.
Prevention of Viral Hepatitis B in Republic of Korea Ok Park, M.D., Ph.D., MPH Vaccine-Preventable Disease Control & National Immunization Program Korea.
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
Milan J. Sonneveld,1 Bettina E. Hansen, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Edward Gane, Yun-Fan Liaw, Qing Xie, E. Jenny Heathcote, Henry.
Interna tional Neurourology Journal 2015;19: Alcohol, Smoking, Physical Activity, Protein, and Lower Urinary Tract Symptoms: Prospective Longitudinal.
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward J. Gane, M.D., Catherine A. Stedman, M.B., Ch.B. New Engl J Med 2013;
Kyung Hee University Hospital 대한소화기학회지 2005;45: 세대 Anti-HCV ELISA 검사의 진단 양성예측도 및 예측 인자 - Anti-HCV ELISA sample/Cutoff 비의 임상 의의를.
The Natural History of Liver Fibrosis Progression Rate in Hepatitis C Infection David Yamini, Benjamin Basseri, Anush Arakelyan, Pedram Enayati, Tram T.
Quali differenze in rapporto al sesso nella monoinfezione HCV PITER cohort data Loreta Kondili Istituto Superiore di Sanità.
Ki Tae Suk, MD 1, Dong Joon Kim, MD 1, Chang Hoon Kim, BS 2, Seung Ha Park, MD 3, Jai Hoon Yoon, MD 1, Yeon Soo Kim, MD 1, Gwang Ho Baik, MD 1, Jin Bong.
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
INTRODUCTION. The annual incidence of liver transplant outcomes in South America has been unknown. So far direct correlations have been reported between.
Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.
HBV. Overview of the Epidemiology of Hepatotropic Viruses.
Date of download: 9/17/2016 From: The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions Ann Intern Med. 2014;161(3):
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
Treatment of HBV/HCV Coinfection
Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B : A Randomized International Study of Entecavir.
Dr. Mohammed Omar Khalifa
National Hepatitis C Database
Effectiveness of Sofosbuvir in terms of sustained virological response at 12 weeks after treatment (SVR12) BETWEEN treatment naïve AND treatment.
3rd International HIV/Viral Hepatitis Co-Infection Meeting HIV/Viral Hepatitis: Improving Diagnosis, Antiviral Therapy and Access Sunday, 17 July.
Volume 67, Issue 3, Pages (September 2017)
Dr Iyat Abdul Sattar A study on the clinical & serolological markers of HBV among patients with chronic HBV infection in Babylon Dr Monem Makki Alshok.
Prevalence of Hepatitis C Virus Genotypes in Bangladesh
Hepatology Hepatitis C virus (HCV) genotype 1b as a risk factor
HBV Management in 2012… Where Are We Heading?
Talking to Patients About HCV Treatment
HCV. The Spectrum of Hepatitis C Virus Infection: From Acute Infection to End-Stage Liver Disease.
Starting Strong: Initial Evaluation of the Patient With HCV
World Epidemiology. Are HIV and Other Chronic Diseases Models Applicable to Viral Hepatitis? Focus on HCV.
Hepatology Hepatitis C virus (HCV) genotype 1b as a risk factor
HEPATOCELLULAR CARCINOMA (HCC) at
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Virological tools to diagnose and monitor hepatitis C virus infection
Impact of metabolic risk factors on HCC
Hepatitis B Virus Load in Serum Does Not Reflect Histologic Activity in Patients With Decompensated Cirrhosis  Jin Dong Kim, Jong Young Choi, Si Hyun.
Volume 67, Issue 3, Pages (September 2017)
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Mun Hyuk Seong,1 Ho Kil,1 Young Seok Kim,2 Si Hyun Bae,3 Youn Jae Lee,4 Han Chu Lee,5 Byung Hak Kang,6 and Sook-Hyang Jeong1* Clinical and Epidemiological Features of Hepatitis C Virus Infection in South Korea: A Prospective, Multicenter Cohort Study Pf. 심 재준 / R1. 오 신주 Journal of Medical Virology 85:1724–1733 (2013)

Introduction Hepatitis C virus (HCV) one of the major causes of chronic liver disease worldwide, affecting approximately 170 million individuals. Patients infected with HCV are at high risk of chronic hepatitis, cirrhosis, and hepatocellular carcinoma(HCC). Studies on the risk factors of HCV infection are limited in Asian countries. HBV infection prevails, and HCV-related liver disease may be under- recognized or of less concern in these regions.

Introduction The importance of HCV infection as a cause of liver disease in the new era of HCV therapeutics with direct-acting antiviral agents. However, clinical studies on the current status of HCV infection have been limited in Korea, especially during the last 10 years In the present stduy, Epidemiological and clinical characteristics of HCV infection in Korea were investigated Identified risk factors related to HCV infection HCV cohort VS Comparison group with chronic liver disease unrelated to HCV or HBV infection who visited the same hospitals (non-B non-C liver disease group).

Methods Prospective, multicenter cohort 1,173 patients Aged >18 years Positive for anti-HCV antibody by third-generation enzyme immunoassay (EIA) enrolled at five university hospitals January 2007 ~ December Study Design and Patients

Methods Diagnostic categories of HCV-related liver disease Acute hepatitis C – 5% Chronic hepatitis C – 66% Past infection – 3% Cirrhosis – 15% HCC – 10% Study Design and Patients

Methods Non-B, non-C liver disease group Comparison group to the HCV cohort 534 patients with various liver diseases not caused by HCV or HBV Nonalcoholic fatty liver (28.6%) Alcoholic liver disease (16.1%), Cryptogenic liver disease (12.5%), Acute hepatitis A virus infection (8.8%) Toxic hepatitis (6.5%) Autoimmune liver disease (5.4%) Pancreaticobiliary disease (5.4%), Liver abscess (2.6%) Liver cysts and hemangioma (1.8%) Other conditions (12.3%) Wilson’s disease, hepatic tuberculosis, FitzHughCurtis syndrome, Gilbert’s syndrome, and abnormal results of liver function test. Study Design and Patients

Results Demographic and Socioeconomic Status

Comorbidity

Liver biopsy & Antiviral treatment received

Distribution of HCV Genotypes

Independent Risk Factors of HCV Infection in Korea

Frequency of Behavioral Risk Factors

Conclusion HCV-related liver disease was mostly prevalent in middle-aged and older patients with a slight predominance of women in Korea. Approximately 20% of the patients had cirrhosis or HCC. Genotypes 1b and 2a/c were the major genotypes. Antiviral therapy was attempted in a high percentage (43%) of patients.

 The pattern of behavioral risk factors differed according to age, gender, and geographic area.  These epidemiological and clinical features can change dynamically, Continuous monitoring of the epidemiology and clinical characteristics of HCV is warranted in this era of direct-acting antiviral agents for the successful treatment of HCV-related liver disease. Conclusion

Thank you !